Jad Farha1, Shahem Abbarh1, Zadid Haq1, Mohamad I Itani1, Andreas Oberbach2, Vivek Kumbhari1, Dilhana Badurdeen3. 1. Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. 2. Department of Diagnostics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany. 3. Division of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA. dbadurd1@jhmi.edu.
Abstract
PURPOSE OF REVIEW: Obesity is a chronic relapsing disease that results in cardiovascular disease, diabetes mellitus, and non-alcoholic fatty liver disease. Currently, surgery represents the most effective treatment. However, the advent of minimally invasive endoscopic bariatric therapy (EBT) has shifted the treatment paradigm to less invasive, cost-effective procedures with minimal complications and recovery time that are preferred by patients. In this review, we will describe current and future EBTs, focusing on outcomes and safety. RECENT FINDINGS: The endoscope has provided an incisionless portal into the gastrointestinal tract for placement of space-occupying devices and intraluminal procedures. EBTs are no longer solely manipulating anatomic alterations; instead, they aim to improve metabolic parameters such as glycated hemoglobin, low-density lipoprotein, cholesterol, and hepatic indices by targeting the mucosal layer of the gastrointestinal tract. The endoscope has succeeded in facilitating clinically meaningful weight loss and improvement of metabolic parameters. Future, solutions to the obesity epidemic will likely entail genetic testing, evaluation of the microbiome, and delivery of personalized therapy, utilizing combination endoscopic modalities that change the anatomy and physiology of individual patients, with new targets such as the abnormal metabolic signal.
PURPOSE OF REVIEW: Obesity is a chronic relapsing disease that results in cardiovascular disease, diabetes mellitus, and non-alcoholic fatty liver disease. Currently, surgery represents the most effective treatment. However, the advent of minimally invasive endoscopic bariatric therapy (EBT) has shifted the treatment paradigm to less invasive, cost-effective procedures with minimal complications and recovery time that are preferred by patients. In this review, we will describe current and future EBTs, focusing on outcomes and safety. RECENT FINDINGS: The endoscope has provided an incisionless portal into the gastrointestinal tract for placement of space-occupying devices and intraluminal procedures. EBTs are no longer solely manipulating anatomic alterations; instead, they aim to improve metabolic parameters such as glycated hemoglobin, low-density lipoprotein, cholesterol, and hepatic indices by targeting the mucosal layer of the gastrointestinal tract. The endoscope has succeeded in facilitating clinically meaningful weight loss and improvement of metabolic parameters. Future, solutions to the obesity epidemic will likely entail genetic testing, evaluation of the microbiome, and delivery of personalized therapy, utilizing combination endoscopic modalities that change the anatomy and physiology of individual patients, with new targets such as the abnormal metabolic signal.
Authors: Gregory G Ginsberg; Bipan Chand; Gregory A Cote; Ramsey M Dallal; Steven A Edmundowicz; Ninh T Nguyen; Aurora Pryor; Christopher C Thompson Journal: Gastrointest Endosc Date: 2011-11 Impact factor: 9.427
Authors: Sérgio Barrichello; Diogo Turiani Hourneaux de Moura; Eduardo Guimaraes Hourneaux de Moura; Pichamol Jirapinyo; Anna Carolina Hoff; Ricardo José Fittipaldi-Fernandez; Giorgio Baretta; João Henrique Felício Lima; Eduardo N Usuy; Leonardo Salles de Almeida; Flavio M Ramos; Felipe Matz; Manoel Dos Passos Galvão Neto; Christopher C Thompson Journal: Gastrointest Endosc Date: 2019-06-19 Impact factor: 9.427
Authors: Gontrand Lopez-Nava; Reem Z Sharaiha; Eric J Vargas; Fateh Bazerbachi; Galvao Neto Manoel; Inmaculada Bautista-Castaño; Andres Acosta; Mark D Topazian; Manpreet S Mundi; Nikhil Kumta; Michel Kahaleh; Andrea Marie Herr; Alpana Shukla; Louis Aronne; Christopher J Gostout; Barham K Abu Dayyeh Journal: Obes Surg Date: 2017-10 Impact factor: 4.129
Authors: Barham K Abu Dayyeh; Andres Acosta; Michael Camilleri; Manpreet S Mundi; Elizabeth Rajan; Mark D Topazian; Christopher J Gostout Journal: Clin Gastroenterol Hepatol Date: 2015-12-31 Impact factor: 11.382